G&A at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Olema Pharmaceuticals, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Olema Pharmaceuticals, Inc.'s G&A?
- Olema Pharmaceuticals, Inc. (OLMA) reported G&A of $8.75M in Q1 2026.
- How has Olema Pharmaceuticals, Inc.'s G&A changed year-over-year?
- Olema Pharmaceuticals, Inc.'s G&A increased by 106.0% year-over-year, from $4.25M to $8.75M.
- What is the long-term trend for Olema Pharmaceuticals, Inc.'s G&A?
- Over 4 years (2021 to 2025), Olema Pharmaceuticals, Inc.'s G&A has grown at a 0.7% compound annual growth rate (CAGR), from $20.39M to $21M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.